Literature DB >> 16600446

Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis.

Christine Hale1, Frances Bowe, Derek Pickard, Simon Clare, Jean-Francois Haeuw, Ultan Powers, Nathalie Menager, Pietro Mastroeni, Gordon Dougan.   

Abstract

Immunisation of BALB/c mice with a vaccine containing Vi polysaccharide conjugated to the Klebsiella pneumoniae outer membrane 40 kDa protein (rP40), in combination with Escherichia coli heat-labile toxin adjuvant (LT), elicited anti-Vi IgG antibodies after administration using different routes. Testing of the immune serum in opsonisation assays demonstrated the specific enhancement of Vi-positive bacterial uptake by cultured murine bone marrow derived macrophages. Intra-peritoneal challenge of mice immunised with the Vi-based vaccine elicited a degree of protection against virulent Vi+ Salmonella enterica serovar typhimurium (S. typhimurium). In contrast, Vi vaccination did not confer protection against oral challenge with virulent Vi-positive S. typhimurium or S. dublin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600446      PMCID: PMC7224987          DOI: 10.1016/j.vaccine.2006.03.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  55 in total

1.  Physical, chemical, antigenic, and immunologic characterization of polygalacturonan, its derivatives, and Vi antigen from Salmonella typhi.

Authors:  Shousun Chen Szu; Slavomír Bystricky
Journal:  Methods Enzymol       Date:  2003       Impact factor: 1.600

2.  Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever.

Authors:  A L Stone; S C Szu
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

3.  Comparison of ViaB regions of Vi-positive organisms.

Authors:  Y Hashimoto; A Q Khan
Journal:  FEMS Microbiol Lett       Date:  1997-12-01       Impact factor: 2.742

4.  Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.

Authors:  S C Szu; X R Li; R Schneerson; J H Vickers; D Bryla; J B Robbins
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

Review 5.  Neonatal and early life vaccinology.

Authors:  C A Siegrist
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

6.  Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines.

Authors:  W A Keitel; N L Bond; J M Zahradnik; T A Cramton; J B Robbins
Journal:  Vaccine       Date:  1994       Impact factor: 3.641

7.  Complete nucleotide sequence and molecular characterization of ViaB region encoding Vi antigen in Salmonella typhi.

Authors:  Y Hashimoto; N Li; H Yokoyama; T Ezaki
Journal:  J Bacteriol       Date:  1993-07       Impact factor: 3.490

8.  Role of the viaB locus in synthesis, transport and expression of Salmonella typhi Vi antigen.

Authors:  I Virlogeux; H Waxin; C Ecobichon; M Y Popoff
Journal:  Microbiology       Date:  1995-12       Impact factor: 2.777

Review 9.  A new typhoid vaccine composed of the Vi capsular polysaccharide.

Authors:  S A Plotkin; N Bouveret-Le Cam
Journal:  Arch Intern Med       Date:  1995-11-27

10.  Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.

Authors:  Do Gia Canh; Feng-ying Kimi Lin; Vu Dinh Thiem; Dang Duc Trach; Nguyen Dinh Trong; Nguyen Duc Mao; Steven Hunt; Rachel Schneerson; John B Robbins; Chiayung Chu; Joseph Shiloach; Dolores A Bryla; Marie-Claude Bonnet; Dominique Schulz; Shousun C Szu
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.609

View more
  11 in total

Review 1.  Antibodies and Protection in Systemic Salmonella Infections: Do We Still Have More Questions than Answers?

Authors:  Pietro Mastroeni; Omar Rossi
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

2.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

3.  Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

Authors:  F Micoli; S Rondini; I Pisoni; D Proietti; F Berti; P Costantino; R Rappuoli; S Szu; A Saul; L B Martin
Journal:  Vaccine       Date:  2010-11-27       Impact factor: 3.641

4.  A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.

Authors:  Ying-Jie Lu; Fan Zhang; Sabina Sayeed; Claudette M Thompson; Shousun Szu; Porter W Anderson; Richard Malley
Journal:  Vaccine       Date:  2012-03-29       Impact factor: 3.641

5.  In vivo regulation of the Vi antigen in Salmonella and induction of immune responses with an in vivo-inducible promoter.

Authors:  Carole Janis; Andrew J Grant; Trevelyan J McKinley; Fiona J E Morgan; Victoria F John; Jenny Houghton; Robert A Kingsley; Gordon Dougan; Pietro Mastroeni
Journal:  Infect Immun       Date:  2011-03-14       Impact factor: 3.441

6.  An adhesion protein of Salmonella enterica serovar Typhi is required for pathogenesis and potential target for vaccine development.

Authors:  Shubhamoy Ghosh; Krishnendu Chakraborty; Theeya Nagaraja; Surajit Basak; Hemanta Koley; Shanta Dutta; Utpala Mitra; Santasabuj Das
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

7.  Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.

Authors:  Simona Rondini; Francesca Micoli; Luisa Lanzilao; Christine Hale; Allan J Saul; Laura B Martin
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

8.  The capsule-encoding viaB locus reduces intestinal inflammation by a Salmonella pathogenicity island 1-independent mechanism.

Authors:  Takeshi Haneda; Sebastian E Winter; Brian P Butler; R Paul Wilson; Cagla Tükel; Maria G Winter; Ivan Godinez; Renée M Tsolis; Andreas J Bäumler
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

9.  A Salmonella Typhimurium-Typhi genomic chimera: a model to study Vi polysaccharide capsule function in vivo.

Authors:  Angela M Jansen; Lindsay J Hall; Simon Clare; David Goulding; Kathryn E Holt; Andrew J Grant; Piero Mastroeni; Gordon Dougan; Robert A Kingsley
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

10.  The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.

Authors:  M Arcuri; R Di Benedetto; A F Cunningham; A Saul; C A MacLennan; F Micoli
Journal:  PLoS One       Date:  2017-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.